This study is looking into whether it's possible to conduct a clinical trial for young people (ages 12-25) with chronic kidney disease (CKD). We want to see if 40 youth with CKD can be successfully enrolled in a trial using Empagliflozin, a medication already approved for adults with CKD. We also want to explore if taking Empagliflozin for three months can improve test results related to kidney and heart health. You would be randomly assigned to either receive Empagliflozin or continue with your usual care. We are looking for participants with Stage 3-4 CKD, but cannot include individuals with certain conditions like heart disease, diabetes, or a history of organ transplant.

Study design

This is an interventional study planning to enroll 40 participants. Participants will be randomly selected to either receive Empagliflozin or continue with their usual care.

What's involved

Participants will take Empagliflozin or continue usual care for 3 months. The study will measure whether participants complete all study procedures over 4 years.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 4 years to assess completion of study procedures.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.